Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving ...
Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...
They found both previously known and novel mutations significantly linked to EGFR activation and drug response, demonstrating the method's precision and revealing new pathways affecting tumor ...
Vivoryon's VIVA-MIND trial echoed the disappointing Alzheimer’s findings of its VIVIAD trial but offers promise in treating ...
Hosted on MSN4mon
Anticancer drugs show promise in reducing Alzheimer's dementia riskThe present study highlights the potential neuroprotective effects of certain classes of anticancer drugs (antimetabolites, multikinase inhibitors, and EGFR inhibitors) against Alzheimer's disease ...
Specifically, lower activation of the epidermal growth factor receptor (EGFR) signaling pathway occurs following reduced endocytosis. Decreased EGFR pathway activity allows LECs to switch from ...
VIVA-MIND Phase 2 data confirm results of varoglutamstat’s benefit on eGFR in VIVIAD; Company now has two independent double-blind placebo-controlled Phase 2 studies demonstrating a clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback